EGFR and non-small cell lung carcinoma: The phase 1/2 KEYNOTE‐021 study suggested that pembrolizumab plus erlotinib did not improve ORR compared with previous monotherapy studies for patients with advanced NSCLC and sensitizing EGFR mutation.95